- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Purpose Bitcoin ETF
Silver47 Exploration
Syntheia
CI Galaxy Bitcoin ETF
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Spectral Medical announced it has been engaged in an ongoing interactive review process with the FDA, after its acceptance submission for Toraymyxin.
Spectral Medical (TSX:EDT) announced it has been engaged in an ongoing interactive review process with the US Food and Drug Administration (FDA), after its acceptance submission for Toraymyxin.
As quoted in the press release:
Based on the filing acceptance date of July 20, 2017, the Company expects to receive more detailed feedback from the FDA on its PMA submission in the fourth quarter of this year.
Spectral also announced that a full manuscript has been submitted for review by a major international medical journal.
EUPHRATES trial results will be presented at two key medical conferences. The European Society of Intensive Care Medicine Conference (ESICM 2017 LIVE) will be held on September 25, 2017 in Vienna and will include an industry symposium promoting Toraymyxin™ sponsored by Toray Industries Inc.
Click here to read the full press release.
Source: www.marketwired.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.